Abstract
Introduction

Mesenchymal stem cells (MSCs) were first identified by
Friedenstein and his colleagues [1] , who described bone-forming progenitor cells from rat bone marrow. In addition to postnatal bone marrow, MSCs can also be isolated from adipose tissues, foetal liver, blood, bone marrow, lung, cord blood, placenta and umbilical cord [2] [3] [4] [5] [6] [7] . Several 
Biological characterization of mesenchymal stem cells Isolation and culture of human MSCs
Standard conditions for generation of bone marrow derived mesenchymal stromal cultures have been reported [8, 9] . However, the property of plastic adherence itself is not sufficient to obtain purified MSCs, some investigators have tried different methods for isolation of homogenous cell populations [10, 11] . Besides adult bone marrow, researchers in our laboratory have also successfully isolated MSCs from other origins such as foetal lung [12] , pancreas, skin, muscle, bone marrow, cord blood and umbilical cord [13] . [14, 16] due to absence of telomerase activity [17, 18] . Some [89] . Then, Bonner-Weir et al. [90] [91] . Recently, several studies have indicated that MSCs are likely to exist within pancreatic duct and islet. Zhang et al. [92] showed that nestin-positive cells isolated from human foetal pancreas possess the characteristics of pancreatic progenitor cells since they have highly proliferative potential and the capability of differentiation into insulin-producing cells in vitro. Huang et al. [93] further proved that after differentiation the islet-like cell clusters (ICCs) displayed the ability to reverse hyperglycaemia in diabetic mice. Additionally, these nestin-positive pancreatic progenitor cells share many phenotypic markers with MSCs derived from bone marrow [92] . In agreement with these findings, another group [94] [138] . [139] or BETA2/NeuroD [140] protein induced insulin expression in pancreatic ductal progenitor cells. Similarly, Domínguez-Bendala et al. [141] showed that TAT-mediated neurogenin 3 (ngn3) protein transduction stimulated pancreatic endocrine differentiation in vitro. In another research, Gräslund's group [142] [148] . [152] and in vitro [153] . Yet the underlying mechanism of this action remains elusive. Oswald et al. [154] showed the differentiation of expanded adult human BM-MSCs into cells with phenotypic and functional features of endothelial cells. However, Kinnaird et al. [155] demonstrated that MSCs secrete a wide array of arteriogenic cytokines and they contribute to collateral re-modelling in ischaemic limb via paracrine mechanisms. Recently, another two studies suggest that BM-MSCs enhance angiogenesis in wounds of diabetic mice through paracrine effects [156, 157] . (Fig. 1) 
MSCs in culture have a fibroblastic morphology and adhere to the tissue culture substrate. Under current in vitro culture conditions MSCs obtained from young donors can grow to 24-40 population doublings and the proliferative potential of the cells obtained from older donors is more compromised [14]. Afterwards, MSCs enter growth arrest, a phenomenon termed replicative senescence [15]. Replicative senescence is a common characteristic of cultured diploid cells, it is caused by several factors including progressive telomere shortening during continuous subculture in vitro
Phenotypic properties of MSCs
Multi-potent differentiation of MSCs
considered that ductal epithelial cells are likely to be the pancreatic progenitors which can add new ␤ cells by the process of neogenesis. The clonal identification of multi-potent precursor cells from adult mouse pancreas that generate endocrine ␤-like cells were also performed
(ii) the ability of the virus to infect primary and second cell lines in vitro; (iii) although the virus enters the nucleus it does not integrate with the host DNA and is therefore not likely to unmask oncogenes, it functions separate to the host DNA as an episome; (iv) most patients have already had contacts with the herpes I virus, which normally resides in a quiescent state in neurological tissue; (v). immune reaction against the virus is relatively mild; (vi) established antiviral treatment against the herpes virus is available. In consequence, the modified herpes I virus could serve as a new vector for human insulin gene delivery into MSCs. (Table 2)
Induction of IPCs from stem cells by protein transduction technology
New technology, known as protein transduction technology, has been recently developed. A variety of peptides, known as protein transduction domains (PTDs) or cell-penetrating peptides (CPPs), have been characterized for their ability to translocate into live cells. Proteins and peptides can be directly internalized into cells when synthesized as recombinant fusion proteins or covalently cross-linked to PTDs. There are numerous examples of biologically active full-length proteins and peptides that have been delivered to cells both in vitro and in vivo. The most commonly studied PTDs are homeodomain transcription factors such as Antennapedia (Antp), HSV type 1 protein VP22 and HIV-1 transactivator TAT protein. The mechanism of PTD-mediated protein transduction is mainly via endocytosis followed by passage from the vesicle into the cytoplasm
It has been suggested that protein transduction technology is useful for the treatment of diabetes, because this technology facilitates the differentiation of stem cells into insulin-producing cells. First, PDX-1 protein and BETA2/NeuroD protein, two pancreatic endocrine transcription factors, both have a PTD sequence in their structure. Noguchi et al. demonstrated that PDX-1
reported that the third helix of the homeodomain of transcription factor Isl-1 internalized into cells. Thus, delivery of exogenous transcription factors (PDX-1, BETA2/NeuroD, ngn3, Isl-1, etc.) by protein transduction technology could be a novel strategy for generating IPCs from stem/progenitor cells without requiring gene transfer technology. We propose MSCs as strong candidate stem cells for this new approach.
Minimum requirements for replacement ␤-cells
As mentioned above, insulin-producing cells generated either by transdifferentiation of MSCs or by delivery of insulin gene into
MSCs for therapeutic neovascularization in type 1 diabetes
It has been demonstrated that endothelial progenitor cells (EPCs) are responsible for postnatal vasculogenesis in physiological and pathological neovascularization [146]. Ischaemia and tissue injury are potent stimuli for neovascularization. We have reported that autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (M-PBMSCs) improves critical limb ischaemia (CLI) in diabetes [147]. Further investigation indicated that local transplantation of M-PBMNCs achieved therapeutic neovascularization via supply of abundant angioblasts (EPCs) and angiogenic factors
An increasing bulk of evidence supports that release of angiogenic factors rather than endothelial transdifferentiation is accountable for MSCs-mediated strengthened angiogenesis. MSCs express genes encoding a broad spectrum of arteriogenic/angiogenic cytokines including vascular endothelial growth factor (VEGF),
Fig. 1 Mesenchymal stem cells in the treatment of type 1 diabetes. The clinical potentials of mesenchymal stem cells (MSCs
Concluding remarks
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